Skip to main content
ImmuneCited

Beta-Glucan per Upper Respiratory Tract Infections

A

Meta-analysis of 13 randomized controlled trials shows yeast beta-glucan may help reduce the incidence, number of episodes, and duration of upper respiratory tract infections compared to placebo. A 16-week RCT with 162 participants found 25% reduction in symptomatic cold infections.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'immunecited.com'; const params = 'ingredient\u003Dbeta\u002Dglucan\u0026condition\u003Dupper\u002Drespiratory\u002Dinfections'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

In sintesi

Meta-analysis of 13 randomized controlled trials shows yeast beta-glucan may help reduce the incidence, number of episodes, and duration of upper respiratory tract infections compared to placebo. A 16-week RCT with 162 participants found 25% reduction in symptomatic cold infections.

Key Study Findings

Randomized Controlled Trial
The anti-infective effect of β-glucans in children.
Dose: 10 mg vs: Placebo Outcome: Body weight Effetto: None None

Popolazione: None

In Vitro
Dry blood spot samples to monitor immune-associated mRNA expression in intervention studies: Impact of Baker's …
Dose: 250 mg/d vs: None Outcome: oxidative stress markers Effetto: None None

Popolazione: None

Randomized Controlled Trial 12 weeks Double-blind
β -Glucan Improves Protective Qi Status in Adults with Protective Qi Deficiency-A Randomized, Placebo-Controlled, and …
Dose: None vs: Placebo Outcome: Protective Qi status improvement Effetto: None None

Popolazione: Adults with Protective Qi deficiency

Meta-Analysis
Effects of yeast β-glucans for the prevention and treatment of upper respiratory tract infection in …
Dose: 95% vs: placebo Outcome: None Effetto: OR = 0.345 p < 0.001

Popolazione: healthy subjects

Randomized Controlled Trial n=69
Soluble and Insoluble Yeast β-Glucan Differentially Affect Upper Respiratory Tract Infection in Marathon Runners: A …
Dose: 250 mL/d vs: Placebo Outcome: None Effetto: None None

Popolazione: URTI patients

Randomized Controlled Trial n=132 Double-blind
Beverage Containing Dispersible Yeast β-Glucan Decreases Cold/Flu Symptomatic Days After Intense Exercise: A Randomized Controlled …
Dose: 250 mL/d vs: Placebo Outcome: None Effetto: None p < .05

Popolazione: URTI patients

Key Statistics

13

Studi

2000

Partecipanti

Positive

A

Grado

Referenced Papers

International journal for … 2024 5 citazioni

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Dosaggi di uso comune

general:
250-500 mg/day
immunesupport:
250-750 mg/day

Limite massimo: No established UL

Dosaggi studiati nella ricerca

Dosaggio Durata Effetto N
10 mg -- Positive --
250 mg/d -- Positive --
None 12 weeks Positive --
95% -- Positive --
250 mL/d -- Mixed 69
250 mL/d -- Neutral 132
900 mg 16.0 weeks Positive 299
367 mg 12.9 weeks Positive 34

Momento migliore per l'assunzione: On empty stomach for optimal immune activation

Safety & Side Effects

Effetti collaterali segnalati

  • Generally very well tolerated
  • Mild gastrointestinal effects (bloating)
  • Allergic reactions in yeast-sensitive individuals

Interazioni note

  • Immunosuppressant medications (may counteract immunosuppression)
  • Generally few known drug interactions

Livello di assunzione massimo tollerabile: No established UL

Consultare sempre il proprio medico prima di iniziare qualsiasi integratore.Consultate sempre il vostro medico prima di iniziare qualsiasi integratore.

Frequently Asked Questions

Does Beta-Glucan help with Upper Respiratory Tract Infections?
Based on 13 studies with 2,000 participants, there is strong evidence from multiple clinical trials that Beta-Glucan may support Upper Respiratory Tract Infections management. Our evidence grade is A (Strong Evidence).
How much Beta-Glucan should I take for Upper Respiratory Tract Infections?
Studies have used various dosages. A commonly studied range is 250-500 mg/day. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Beta-Glucan?
Reported side effects may include Generally very well tolerated, Mild gastrointestinal effects (bloating), Allergic reactions in yeast-sensitive individuals. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Beta-Glucan and Upper Respiratory Tract Infections?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 13 peer-reviewed studies with 2,000 total participants. The overall direction of effect is positive.

Related Evidence

Altri ingredienti per Upper Respiratory Tract Infections

Avvertenza FDA: Queste affermazioni non sono state valutate dalla Food and Drug Administration. I prodotti e le informazioni presenti su questo sito web non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. I gradi di evidenza presentati si basano sulla nostra analisi della ricerca pubblicata e sottoposta a revisione paritaria e non costituiscono consulenza medica. Consultate sempre il vostro medico prima di iniziare qualsiasi regime di integrazione.